TrialDrug safety2019

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma.

Mats Carlsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.